Navigation Links
Abviva Details Patent Information for its Breast Cancer Risk Assessment Technology
Date:5/21/2010

SANTA BARBARA, Calif., May 21 /PRNewswire-FirstCall/ -- Abviva, Inc. (Pink Sheets: ABVV), a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, today provided further details about worldwide patent protection for its breast cancer risk assessment technology.  

The Company previously announced that the Japanese Patent Office issued two patents on the core technology that may be used for therapeutic applications and in the Company's breast cancer risk assessment test, the Mammastatin Serum Assay (MSA). The patents are the most recent of 13 international and U.S. patents to issue to the University of Michigan for breast cancer diagnostic and therapeutic uses of Mammastatin.

The international patents detail methods of use and compositions of Mammastatin in therapeutic and diagnostic applications in the United States (7 patents), Australia (2 patents), Canada (1), Europe (1), and Japan (2). These patents have issued starting in the United States and Australia in 2002, and continuing through the two most recent patents issued this year in Japan.

"Based upon the patents, we believe that we will be able to aggressively penetrate the largest markets worldwide with confidence that our intellectual property is secure," said Barrett Evans, CEO of Abviva. "There are additional patents that have been filed and we are hopeful that we will be able to obtain even further protection of our intellectual property as the Co
'/>"/>

SOURCE Abviva, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Abviva Announces Further Patent Issuance for Technology Used in Breast Cancer Diagnostics and Therapeutics
2. Details Issued Today on $1 Billion in Biotech Tax Credits and Grants
3. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
4. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2009 Earnings Conference Call and Webcast
5. Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market
6. Cequent to Provide Details at BIOCOM About Planned Launch of its Clinical Program - 3 p.m., Tuesday, October 27
7. Oncolytics Biotech(R) Inc. Announces Details of 2009 Annual Shareholder Meeting
8. CryoLife Announces Release Date and Teleconference Call Details for 2009 First Quarter Financial Results
9. White Paper Details How DNA Sequencing Services Can Prevent Cleanroom Shutdowns at Medical Device and Pharmaceutical Manufacturers
10. In Analyst Interview, Cord Blood America Provides Details of Special Shareholder Meeting
11. Shire plc: Change to Directors Details
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , a precision medicine software company that has developed a ... genomic, imaging and other biomedical data in research and clinical ... CEO of Aspera, an IBM Company, to its board as ... "We are pleased to welcome Michelle to ...
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
(Date:12/24/2014)... Wash. , Dec. 24, 2014   BioLife Solutions , ... and marketer of proprietary clinical grade hypothermic storage ... shipping products for cells and tissues  ("BioLife" or the ... Meeting of Stockholders on May 4, 2015 (the "Annual Meeting"). ...
(Date:12/24/2014)... 23, 2014 Earlier this year in a ... of the Adult Stem Cell Technology Center, LLC ( ASCTC ... unique property of adult tissue stem cells. His title ... Important for the Future,” embodied the essence of his message ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... Calif., Feb. 4 Arryx, Inc.,announced the addition ... Holographic Optical Trapping ("HOT") product line. The HOTkit,Complete ... events, and now, through the power of light, ... The HOTkit Complete was unveiled February 4 ...
... HORSHAM, Pa., Feb. 4 Centocor, Inc. announced ... (CNTO 1275),has been accepted for review by the ... of adult patients with chronic moderate to severe ... with a novel,mechanism of action that targets the ...
... HAVEN, Conn., Feb. 4 VION,PHARMACEUTICALS, INC. (Nasdaq: ... the Company,s senior management team as Vice President,Medical., ... pleased,to have Bill Hahne joining Vion in medical affairs. ... will be extremely useful to our,efforts to file a ...
Cached Biology Technology:Arryx Launches HOTkit(TM) Complete for Dynamic, Scientific Manipulation of Microscopic Elements 2Arryx Launches HOTkit(TM) Complete for Dynamic, Scientific Manipulation of Microscopic Elements 3Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA 2Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA 3Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team 2Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team 3
(Date:12/19/2014)... Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has announced the ... Apple/AuthenTec TMDR92 & Sapphire - Technology Report" report ... Following the acquisition of AuthenTec in ... the iPhone 5S. It is currently the only device ...
(Date:12/17/2014)... , Dec. 15, 2014 The Defense Logistics ... to detect and prevent counterfeit microcircuits from entering into ... performing an in-house microcircuit anti-counterfeit initiative dubbed DNA marking. ... while increasing their reliability throughout the supply chain. The ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a technology ... measures the overall facial feature of a person such ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... specific wavelengths can be used to boost an enzyme,s function by ... expensive biofuels, detergents and a host of other products. In ... a team led by Pratul Agarwal of the Department of ... improve upon nature and it happens in the blink of ...
... Saturday, May 5th from 9AM to noon join the ... a special forum exploring hydrofracking. The event,s goal is ... on the natural gas extraction technique, which involves injecting ... thousands of feet underground to release gas trapped in ...
... 17, 2012) Combined, complimentary therapies have the ability ... transplantation for spinal cord repair in rat models, according ... Korean researchers who published in a recent issue of ... http://www.ingentaconnect.com/content/cog/ct/ ., "When transplanted, neural stem cells have ...
Cached Biology News:ORNL process improves catalytic rate of enzymes by 3,000 percent 2Cary Institute Hydrofracking Forum 2Neural stem cell transplants for spinal cord injury maximized by combined, complimentary therapies 2
LabFax: Immunochemistry...
Mycoplasma Removal Agent (MRA) has been developed for cell culture, to combat the widespread problems caused by contamination of cell cultures with mycoplasma....
Request Info...
albumin from bovine serum (BSA), BODIPY® FL conjugate...
Biology Products: